预约演示

更新于：2025-05-07

Ovarian Serous Tumor

卵巢浆液性肿瘤

更新于：2025-05-07

基本信息

别名

Ovarian Serous Neoplasm、Ovarian Serous Tumor、Serous Neoplasm of Ovary

+ [6]

简介

A benign, borderline, or malignant epithelial tumor of the ovary characterized by the presence of neoplastic epithelial cells that, in well differentiated tumors, resemble the epithelial cells of the fallopian tube and, in poorly differentiated tumors, show anaplastic features. Approximately thirty to fifty percent of the tumors are bilateral. Grossly, the better differentiated tumors consist of cystic masses, usually unilocular, containing a clear but sometimes viscous fluid. Papillary formations are often present. The more malignant tumors tend to be solid and invasive, with areas of necrosis and hemorrhage.

关联

项与卵巢浆液性肿瘤相关的药物

Sirolimus Albumin-Bound

西罗莫司(白蛋白结合型)

靶点

MUT x mTOR

作用机制

MUT刺激剂 [+3]

在研机构

Whitehawk Therapeutics, Inc. [+5]

原研机构

Abraxis BioScience, Inc.

在研适应症

血管周围上皮样细胞肿瘤 [+20]

非在研适应症

晚期肉瘤 [+20]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2021-11-22

Fluzoparib

氟唑帕利

靶点

PARP

作用机制

PARP抑制剂

在研机构

江苏恒瑞医药股份有限公司 [+2]

原研机构

江苏恒瑞医药股份有限公司

在研适应症

gBRCA突变/HER2阴性乳腺癌 [+23]

非在研适应症

晚期癌症 [+6]

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2020-12-11

Selumetinib sulfate

司美替尼

靶点

MEK1 x MEK2

作用机制

MEK1抑制剂 [+1]

在研机构

AstraZeneca UK Ltd. [+11]

原研机构

Array BioPharma, Inc.

在研适应症

神经纤维瘤病 [+64]

非在研适应症

急性早幼粒细胞白血病 [+68]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-04-10

项与卵巢浆液性肿瘤相关的临床试验

NCT05956093

/ Not yet recruitingN/AIIT

FAST HOC-FAPI PET for Staging of High-Grade Serous Ovarian Cancer .

The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
The purpose of this study is to find out if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans.

开始日期2025-03-24

申办/合作机构

University Health Network

NCT06799065

/ Recruiting临床1期

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

开始日期2025-03-21

申办/合作机构

Accent Therapeutics, Inc.

NCT06494150

/ Recruiting临床2期IIT

Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).

开始日期2024-12-26

申办/合作机构

University of Oklahoma

[+1]

100 项与卵巢浆液性肿瘤相关的临床结果

登录后查看更多信息

100 项与卵巢浆液性肿瘤相关的转化医学

登录后查看更多信息

0 项与卵巢浆液性肿瘤相关的专利（医药）

登录后查看更多信息

2,746

项与卵巢浆液性肿瘤相关的文献（医药）

2025-05-13·Oncogene

Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer

Article

作者: Yu, Lianbo ; Conrads, Thomas ; Wagner, Vincent ; Sakaue, Takahiko ; Maxwell, G Larry ; Morton, Molly ; Cohn, David E ; Selvendiran, Karuppaiyah ; Dorayappan, Kalpana Deepa Priya ; Backes, Floor ; Gonzalez, Anna ; Wang, Qi-En ; Cosgrove, Casey ; O'Malley, David M

AbstractPlatinum resistance in high-grade serous ovarian carcinoma (HGSOC) portends a poor prognosis. Although initial platinum-based chemotherapy response rates are high, 15-20% of patients demonstrate primary resistance to platinum therapy and almost all patients will develop platinum resistance in the recurrent setting. No predictive or diagnostic biomarkers have been utilized specific to platinum resistance. This study aimed to identify candidate biomarkers for platinum resistance in HGSOC using an extracellular vesicle (EV) based approach. We found differentially expressed and distinct EV proteins, namely TMEM205 and CFH, in patients with platinum-resistant (PR) HGSOC compared to those of platinum-sensitive (PS) patients, utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS). Expression of these EV proteins were validated in patient-derived PR cell lines as well as in clinically relevant mouse models of HGSOC post-platinum therapy. We corroborated these findings using serum samples from patients with PS and PR-HGSOC. Both EV CFH and EV TMEM205 exhibited excellent diagnostic capability for PR as noted by receiver operating characteristic curves with area under the curve values of 0.95 and 0.84, respectively. The high diagnostic performance of TMEM205 and CFH within EVs compared to the relatively poor performance of conventional serum proteins such as Ca125 suggests their robust potential as non-invasive biomarkers for detecting platinum resistance in HGSOC. Furthermore, the ROC curve for the combined biomarker demonstrated excellent diagnostic performance, with an AUC of 0.973, a true positive rate (TPR) of 0.938, and a false positive rate (FPR) of 0.062. Incorporating this multi-protein biomarker panel alongside established biomarkers further enhances diagnostic accuracy. Serum EV CFH and TMEM205 are promising biomarkers for early detection of platinum resistance in HGSOC and may highlight underlying chemoresistance mechanisms, offering potential future therapeutic targets.

2025-05-01·European Journal of Cancer Prevention

Prevalence of BRCA1 and BRCA2 mutations in ovarian cancer patients from Yunnan Province in southwest China

Article

作者: Peng, Yongmei ; Zhang, Lei ; Zhou, Yongchun ; Yang, Hongying ; Liao, Jiaqian ; Jia, Yue ; He, Xian

Carriers with germline breast cancer 1/2 gene mutations (BRCAm) are likely to develop ovarian cancer (OC). Therefore, identifying these mutations may enable individualized therapy for OC and preventive measures to reduce OC risk in BRCAm carrier families. Thus, we investigated the prevalence of BRCAm in OC patients from Yunnan Province in Southwest China. In total, 674 unselected OC patients were enrolled and tested for BRCAm via next-generation sequencing. Data on clinicopathological characteristics and personal/family history of cancer were collected. The prevalence rates of pathogenic/likely pathogenic BRCAm were 26.6% overall, 20.8% among BRCA1m carriers, 5.5% among BRCA2m carriers, and 0.3% among carriers of both BRCA1m and BRCA2m. The most common pathogenic mutation in the BRCA1 gene was c.5114T>C (n = 9). The number of BRCAm carriers was significantly greater among patients with serous cancer, a personal tumor history, a family history of hereditary breast and ovarian cancer (HBOC)-related tumors, and bilateral tumors. The most common pathogenic mutation in this cohort was c.5114T>C (n = 9) in BRCA1. The prevalence and spectrum of BRCAm in OC patients from Yunnan Province are different from those in other groups. BRCA status testing is advised for all OC patients, particularly those with a family history of HBOC.

2025-04-03·Current Medicinal Chemistry

Immunogenic Cell Death-relevant Molecular Patterns, Prognostic Genes, and Implications for Immunotherapy in Ovarian Cancer

Article

作者: Li, Jia ; Zhang, Yinbin ; Gong, Pijun ; Zhang, Shuqun

Background:Ovarian cancer (OV) is one of the deadliest gynecologic cancers, and approximately 75% of serous ovarian cancer [SOC] patients are diagnosed at advanced stages due to the lack of effective biomarkers.Objective:Immunogenic cell death (ICD) has been investigated in many comprehensive studies, and the role of ICD in ovarian cancer and its impact on immunotherapy is not yet known.Method:The NMF clustering analysis was employed to categorize OV samples into different subgroups. Survival, mutation, and CNV analyses were performed in these clusters. ESTIMATE, CIBERSORT, TIDE, and drug sensitivity analyses [based on GDSC] were also performed on the subtypes. Then, differentially expressed immunogenic cell death genes (DE-ICDGs) in OV were obtained by crossing the DEGs between cluster 3 vs cluster 1, DEGs from the TCGA-GTEx dataset, and DEGs from the GSE40595 dataset. Functional enrichment analysis of DE-ICDGs was then performed. The signature genes related to the prognosis of OV in three OV datasets were excavated by drawing Kaplan-Meier curves. Finally, quantitative real-time PCR [qRT-PCR] was performed to verify the expression trends of the signature genes.Results:The NMF clustering analysis categorized OV samples into three distinct groups according to the expression levels of ICDGs, with differential analysis indicating that Cluster 3 represented the subgroup with high ICD expression. Mutation and CNV analysis did not differ significantly between clusters, but Amp and Del's numbers did. Immuno- infiltration analysis revealed that cluster 3 showed significant differences from cluster 1 and cluster 2. Immunotherapy and drug sensitivity analysis showed differences in immunotherapy and chemotherapy sensitivity between the clusters. The DEGs in cluster3 vs. cluster1, TCGA-GTEx dataset and GSE40595 dataset were intersected to obtain a total of 71 DE-ICDGs, and functional enrichment result suggested that the DE-ICDGs were significantly correlated with inflammatory response, complement system and positive regulation of cytokine production. 2 DE-ICDGs (FN1 and LUM) were identified that were associated with OV prognosis and were validated significantly down-regulated in the SOC group with PCR.Conclusion:We identified ICD-associated subtypes of OV and mined 2 OV prognostic genes (FN1 and LUM) associated with ICD, which may have important implications for OV prognosis and therapy.conclusion:We identified ICD-associated subtypes of OV and mined 2 OV prognostic genes (FN1 and LUM) associated with ICD by analyzing transcriptome data and clinical data of OV from public databases, which may have important implications for OV prognosis and therapy.

102

项与卵巢浆液性肿瘤相关的新闻（医药）

2025-04-24

·CityofHope希望之城

智慧抗癌新纪元：希望之城携AI与免疫疗法突破亮相美国癌症研究协会 (AACR) 2025 年年会

本届年会共设 74 余场专题会议，包括主席论坛、全体大会、教育专场、小型研讨会及海报展示等，将集中呈现乳腺癌、鼻咽癌、结肠癌及其他癌症领域的最新技术突破与创新疗法。作为美国最大的癌症研究与治疗机构之一的希望之城（其国家医疗中心被《美国新闻与世界报道》评为全美顶尖五大癌症中心之一），其科研团队将亮相2025年4月25日至30日在芝加哥举行的美国癌症研究协会（AACR）年度大会，展示其最新科研成果。John D. CarptenPh.D.希望之城专家团队将出席 74 余场各类学术活动，内容涵盖：人工智能与多组学等前沿技术在肿瘤研究中的应用、自然杀伤细胞临床治疗新进展、重大临床试验成果发布，以及通过社区参与推动科研政策转化等重大议题。希望之城首席科学官、Irell & Manella 癌症中心主任特聘教授、贝克曼研究所 Morgan & Helen Chu 冠名主任 John D. Carpten 表示：“希望之城科研团队在 AACR 大会上展示的研究成果，其广度和深度充分彰显了我们'让希望照进每位癌症患者'的使命。我们深感自豪能与大家分享我们通过科学探索、临床创新与人文关怀的融合不断开发的创新技术与疗法。”主席会议希望之城贝克曼研究所综合转化科学系创始主任 David W. Craig 教授将压轴主持大会闭幕全会“预测肿瘤学的机遇”。该专场将聚焦探索前沿计算技术、生物医学与临床手段，通过多维度肿瘤研究推动精准医疗发展。PL05专场将于2025年4月30日星期三上午8:00-10:00举行。David W. CraigPh.D.Craig 博士介绍道：“本专场将展现领域前沿工作者如何运用尖端技术突破个体化诊疗边界。通过整合多维数据，我们能够更精准解析治疗耐药机制，优化预测模型，最终提升精准医疗效果。” 此外，Craig博士还将主持“人工智能与数据科学在癌症机理研究中的应用”教育专场，并发表关于运用多组学技术解析实体瘤异质性基因组特征的研究报告。 “人工智能与数据科学加速癌症研究：多尺度多模态整合的深度解析”教育专场（ED04）将于2025年4月25日星期五16:45-18:15举行。Craig 博士将带来首场报告，题为“多组学基因组技术解析实体瘤空间亚克隆异质性”。Craig 博士实验室的研究生 Nina (Jiarong) Song 将在“人工智能与机器学习在基础转化研究中的应用”小型研讨会（MS.BCS01.01：2025年4月27日星期日15:00-17:00举行）作开场报告。其研究通过深度学习整合数字病理、基因组学与空间转录组数据，为胶质母细胞瘤、三阴性乳腺癌和结直肠癌的进展机制提供新见解，报告题为“深度学习解码肿瘤微环境：空间转录组与组织病理学的融合创新”。Michael CaligiuriM.D.希望之城国家医疗中心前院长、血液与造血细胞移植系教授 Michael A. Caligiuri 博士将主持两场教育专场。其中“自然杀伤细胞：基础生物学与临床应用新进展”（ED57专场2025年4月26日星期六10:00-11:30）将由 Caligiuri 博士作开场报告，重点介绍包括 NK 细胞在内的先天免疫淋巴细胞研究。NK 细胞作为具有抗癌潜力的白细胞，现已成为希望之城重点研究的治疗手段。 Caligiuri 博士还将主持“学术创业：从实验室到病床的转化之路（上篇）”教育专场（ED54），该专场将于2025年4月26日星期六上午8:00-9:30举行，重点探讨如何将基础研究成果转化为临床应用。希望之城的科学家和医学专家将带来以下重要报告 “新型抗体偶联药物（ADC）的毒性管理与预测” 新近加入希望之城并担任女性癌症项目主任的 Hope Rugo 医学博士，将在“诊断与治疗新进展”专场（ADT04：2025年4月28日星期一13:25-13:45）分享其在抗体偶联药物毒性管理方面的最新研究成果。此外，Rugo 博士还将作为特邀讨论嘉宾，出席4月29日星期二10:15-12:15举行的“生物制剂与T细胞衔接器临床试验”全体会议。 “基于空间转录组学的多组学分析：西班牙裔/拉丁裔早发性结直肠癌患者MYC基因与WNT信号通路变异研究” 来自 Enrique Velazquez Villarreal 博士实验室的博士后研究员、综合转化科学系助理教授 Francisco (Paco) Carranza，将在小型研讨会发表题为“基于多组学分析的西班牙裔/拉丁裔青年早发性结直肠癌研究：提升弱势群体精准医疗水平”的专题报告。（小型研讨会 3742，2025年4月28日周一14:35-14:50） “PM-AI 代理：会话式人工智能系统通过整合临床、基因组和健康社会决定因素数据分析，实现精准医疗和促进健康公平” Villarreal 博士团队还将展示其研发的“ PM-AI 智能诊疗系统”（海报展示1115/1：2025 年4月27日星期日14:00-17:00）。该人工智能平台通过整合临床数据、基因组特征及社会健康决定因素，构建对话式精准医疗系统，致力于解决医疗资源分配不均等问题。 “派安普利单抗（Penpulimab）联合化疗对照安慰剂联合化疗一线治疗复发/转移性鼻咽癌的全球多中心 Ⅲ 期随机双盲临床试验（AK105-304）” 肿瘤内科专家 Aditya Shreenivas 医学博士将在临床试验专场（小型讨论会 CT011：2025年4月27日星期日15:50-16:00）公布作为人源化抗 PD-1 单克隆抗体的派安普利单抗在晚期鼻咽癌患者中的Ⅲ期临床试验最新数据。 “破解雌激素受体阳性(ER+)乳腺癌细胞周期抑制耐药性的内在机制” 肿瘤内科&治疗研究系 Andrea Bild 教授实验室博士后研究员 Kimya Karimi，将展示一项希望之城的最新研究成果。该研究针对雌激素受体阳性乳腺癌原发性内分泌治疗耐药这一临床难题，创新性地探索了联合治疗方案。（小型研讨会编号6383：2025年4月29日星期二15:05-15:20） “科研转化之道：社区参与推动癌症防治政策落地的科学与艺术” 希望之城社区研究&教育联盟中心创始主任 Kimlin Tam Ashing 教授将在教育专场（ED39：2025年4月25日星期五15:30-15:50）分享其团队在构建社区健康伙伴关系以改善整体健康水平方面的创新实践。重点海报展示精选 Carpten 博士实验室高级研究员 Jing Qian 将在“最新突破”海报专场（LB076/12：2025年4月27日星期日14:00-17:00）展示其作为第一作者运用空间转录组学技术，揭示高级别浆液性卵巢癌对免疫检查点抑制剂产生不同应答的肿瘤微环境特征与免疫调控机制方面的最新研究成果。血液学和肿瘤学研究员 Peter Zang 医学博士作为第一作者，将在海报专场（5103/8：2025年4月29日星期二14:00-17:00）汇报其团队创新成果。研究采用 GeoMx 数字空间分析技术，精准解析了转移性激素敏感性前列腺癌在西班牙裔/拉丁裔与非西班牙裔患者中的差异蛋白表达谱。该研究由医学肿瘤学&治疗研究系 Tanya Barauskas Dorff 教授指导，深入探讨了种族因素与前列腺癌生物学特征的复杂关联。医学肿瘤学&治疗研究系助理教授 Aritro Nath 博士与博士后研究员 Sydney Grant 联合研发的“基于多模态数据与生存变分自编码器的乳腺癌无复发生存预测模型”（海报展示5011/15：2025年4月29日星期二09:00-12:00），创新性地整合临床多组学数据与深度学习技术，为乳腺癌预后评估提供了更精准的预测工具。关于希望之城希望之城的使命是将未来的治愈方法带给今天有所需要的人。希望之城成立于 1913 年，现已发展成为美国最大的癌症研究和治疗机构之一，也是糖尿病和其他危及生命疾病的主要研究中心之一。希望之城的研究为众多突破性癌症药物以及人类合成胰岛素和单克隆抗体奠定了基础。希望之城以美国国家癌症研究所指定的独立性综合癌症中心为核心，为患者带来了独特的综合性护理模式，涵盖了癌症护理、研究和开发、学术和培训以及创新计划。希望之城不断发展的全国性系统包括位于洛杉矶的主院区、遍布南加州的临床护理网点、位于加利福尼亚州橙县的新癌症中心以及位于亚特兰大、芝加哥和凤凰城的治疗网点。希望之城的附属机构包括转化基因组学研究所和 AccessHopeTM 等。如欲了解关于希望之城的更多信息，请通过我们的微信公众号或下方联系方式与我们取得联系。

AACR会议临床结果免疫疗法

2025-04-03

·mendus.com

Data supporting the use of Mendus’ DCOne platform to improve production of ovarian cancer TIL therapies presented at ITOC conference

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that the company has presented data supporting the use of its DCOne platform to expand ovarian cancer tumor-infiltrating lymphocytes (TILs) at the Immunotherapy of Cancer Conference (ITOC). The data support the use of Mendus’ DCOne platform to overcome key hurdles in the production of TIL-based therapies for solid tumor indications. Adoptive cell therapies based on tumor-infiltrating lymphocytes derived from patients’ tumor tissues have proven successful in melanoma and are also being developed as a promising new treatment for other solid tumors. The production of therapeutic quantities of TILs is dependent on reliable methods to massively expand these cells extracted from available tumor material collected via surgery, while maintaining their functional characteristics needed to fight cancer cells upon reinjection. In collaboration with academic collaborators at the University Medical Center Groningen (UMCG), Mendus has explored the use of its proprietary DCOne platform to expand functional TILs from ovarian cancer tissue samples. The data presented during the ITOC conference on April 3 demonstrate that TIL production can be significantly improved with dendritic cells derived from Mendus’ DCOne cell line. Addition of DCOne mDCs resulted in at least five times higher TIL expansion, with the majority being effector-memory T cells. The DCOne platform can therefore be used to improve the quantity and quality of TILs for treatment of patients with ovarian cancer and other solid tumors. Mendus’ DCOne platform provides for GMP-grade, off-the-shelf leukemic-derived dendritic cells. Based on the company’s know-how of dendritic cell biology, Mendus has been working on the ex vivo expansion of immune cells as a basis for novel adoptive cell therapies, including memory NK cells associated with improved survival in blood-borne tumors. The data presented at ITOC indicate that the platform is versatile and can also be used for the production of TILs, an upcoming therapy for solid tumors. Mendus has secured a number of grants to support its research programs and collaborations, including the Oncode Accelerator program and a public-private partnership grant with UMCG from Health~Holland. Mendus has an ongoing clinical collaboration with UMCG for the ALISON study, a Phase I trial evaluating safety and efficacy of Mendus’ lead product vididencel in high-grade serous ovarian cancer patients. For more information, please contact:Erik MantingChief Executive OfficerE-mail: ir@mendus.com About Mendus AB (publ) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ AttachmentsData supporting the use of Mendus’ DCOne platform to improve production of ovarian cancer TIL therapies presented at ITOC conference

免疫疗法临床1期细胞疗法

2025-03-24

·drugs

CA-125 Levels Vary by Patient Race at Ovarian Cancer Diagnosis

MONDAY, March 24, 2025 -- Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer diagnosis, according to a study published online March 20 in JAMA Network Open . Anna Jo Bodurtha Smith, M.D., M.P.H., from the University of Pennsylvania Health Systems in Philadelphia, and colleagues conducted a retrospective cohort study involving all patients with ovarian cancer diagnosed between Jan. 1, 2004, and Dec. 31, 2020, to examine CA-125 levels at ovarian cancer diagnosis by patient race and ethnicity. Of the 250,749 patients included, 0.4, 3.7, 8.6, 85.2, and 2.0 percent were American Indian, Asian, Black, White, and other or unknown race, respectively, and 6.7, 88.8, and 4.6 percent were Hispanic, non-Hispanic, and unknown ethnicity, respectively. Overall, 212,477 had measured CA-125 levels and 88.2 percent had elevated CA-125 levels at diagnosis. The researchers found that the likelihood of having an elevated CA-125 level at ovarian cancer diagnosis was lower for patients of American Indian, Asian, or Black race versus White patients. After adjustment for stage, comorbidities, and menopausal stage, Black and American Indian patients had lower odds of elevated CA-125 than Whites (adjusted odds ratios, 0.77 and 0.77). For patients with high-grade serous ovarian cancer only, the odds of having elevated CA-125 at diagnosis were lower for Black patients (adjusted odds ratio, 0.81). "Further work is needed to develop inclusive CA-125 thresholds and guidelines for an ovarian cancer diagnosis and prevent compounding disparities," the authors write. One author disclosed ties to GlaxoSmithKline. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果